182 related articles for article (PubMed ID: 25596703)
1. Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways.
Hansen SN; Westergaard D; Thomsen MB; Vistesen M; Do KN; Fogh L; Belling KC; Wang J; Yang H; Gupta R; Ditzel HJ; Moreira J; Brünner N; Stenvang J; Schrohl AS
Tumour Biol; 2015 Jun; 36(6):4327-38. PubMed ID: 25596703
[TBL] [Abstract][Full Text] [Related]
2. The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.
Hansen SN; Ehlers NS; Zhu S; Thomsen MB; Nielsen RL; Liu D; Wang G; Hou Y; Zhang X; Xu X; Bolund L; Yang H; Wang J; Moreira J; Ditzel HJ; Brünner N; Schrohl AS; Stenvang J; Gupta R
BMC Genomics; 2016 Jun; 17():442. PubMed ID: 27277198
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Jandu H; Aluzaite K; Fogh L; Thrane SW; Noer JB; Proszek J; Do KN; Hansen SN; Damsgaard B; Nielsen SL; Stougaard M; Knudsen BR; Moreira J; Hamerlik P; Gajjar M; Smid M; Martens J; Foekens J; Pommier Y; Brünner N; Schrohl AS; Stenvang J
BMC Cancer; 2016 Jan; 16():34. PubMed ID: 26801902
[TBL] [Abstract][Full Text] [Related]
4. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
Braunstein M; Liao L; Lyttle N; Lobo N; Taylor KJ; Krzyzanowski PM; Kalatskaya I; Yao CQ; Stein LD; Boutros PC; Twelves CJ; Marcellus R; Bartlett JM; Spears M
Breast Cancer Res; 2016 Feb; 18(1):16. PubMed ID: 26852132
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells.
Reed K; Hembruff SL; Laberge ML; Villeneuve DJ; Côté GB; Parissenti AM
Epigenetics; 2008 Sep; 3(5):270-80. PubMed ID: 19001875
[TBL] [Abstract][Full Text] [Related]
8. MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition.
Zhang Y; Wang Y; Wei Y; Li M; Yu S; Ye M; Zhang H; Chen S; Liu W; Zhang J
Sci Rep; 2015 Oct; 5():15424. PubMed ID: 26487539
[TBL] [Abstract][Full Text] [Related]
9. Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.
Sprowl JA; Reed K; Armstrong SR; Lanner C; Guo B; Kalatskaya I; Stein L; Hembruff SL; Tam A; Parissenti AM
Breast Cancer Res; 2012 Jan; 14(1):R2. PubMed ID: 22225778
[TBL] [Abstract][Full Text] [Related]
10. miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression.
Yao YS; Qiu WS; Yao RY; Zhang Q; Zhuang LK; Zhou F; Sun LB; Yue L
Oncol Rep; 2015 May; 33(5):2504-12. PubMed ID: 25813250
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
De Iuliis F; Salerno G; Giuffrida A; Milana B; Taglieri L; Rubinacci G; Giantulli S; Terella F; Silvestri I; Scarpa S
Tumour Biol; 2016 Feb; 37(2):2603-11. PubMed ID: 26392111
[TBL] [Abstract][Full Text] [Related]
12. Prostate apoptosis response 4 (PAR4) expression modulates WNT signaling pathways in MCF7 breast cancer cells: A possible mechanism underlying PAR4-mediated docetaxel chemosensitivity.
de Bessa Garcia SA; Pavanelli AC; Cruz E Melo N; Nagai MA
Int J Mol Med; 2017 Apr; 39(4):809-818. PubMed ID: 28259909
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of docetaxel sensitivity by miR-638 via regulation of STARD10 pathway in human breast cancer cells.
Zhao G; Li Y; Wang T
Biochem Biophys Res Commun; 2017 May; 487(2):255-261. PubMed ID: 28412359
[TBL] [Abstract][Full Text] [Related]
15. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
[TBL] [Abstract][Full Text] [Related]
16. Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern.
Işeri OD; Kars MD; Gündüz U
Mol Biol Rep; 2012 Apr; 39(4):3505-16. PubMed ID: 21720762
[TBL] [Abstract][Full Text] [Related]
17. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
Ooe A; Kato K; Noguchi S
Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
[TBL] [Abstract][Full Text] [Related]
18. lncRNA profile study reveals the mRNAs and lncRNAs associated with docetaxel resistance in breast cancer cells.
Huang P; Li F; Li L; You Y; Luo S; Dong Z; Gao Q; Wu S; Brünner N; Stenvang J
Sci Rep; 2018 Dec; 8(1):17970. PubMed ID: 30568280
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of resistance to cabazitaxel.
Duran GE; Wang YC; Francisco EB; Rose JC; Martinez FJ; Coller J; Brassard D; Vrignaud P; Sikic BI
Mol Cancer Ther; 2015 Jan; 14(1):193-201. PubMed ID: 25416788
[TBL] [Abstract][Full Text] [Related]
20. Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters.
Němcová-Fürstová V; Kopperová D; Balušíková K; Ehrlichová M; Brynychová V; Václavíková R; Daniel P; Souček P; Kovář J
Toxicol Appl Pharmacol; 2016 Nov; 310():215-228. PubMed ID: 27664577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
